Metal-Organic Framework-Based Drug Delivery Systems for Cancer Therapy: A Review.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Metal-Organic Frameworks*/chemistry ; Neoplasms*/drug therapy ; Drug Delivery Systems*/methods ; Antineoplastic Agents*/chemistry ; Antineoplastic Agents*/administration & dosage ; Antineoplastic Agents*/therapeutic use ; Drug Carriers*/chemistry; Humans ; Animals

Cancer remains one of the most significant global health challenges, with conventional treatments limited by side effects and resistance to drugs. The unique properties of metal-organic frameworks (MOFs), which offer high surface areas, tunable structures, and biodegradable properties, make them promising candidates for cancer therapy. This review focuses on MOF-based drug delivery systems for cancer treatment in biomedical applications. This article discusses various synthesis methods, drug-loading strategies, and cytotoxicity considerations. The relationship between the basic chemistry of MOFs and their biomedical applications is elucidated by how each feature directly affects MOF performance in cancer drug delivery. Therefore, this review is a practical and complete guide for researchers working to translate MOFs into effective cancer treatments. Moreover, the role of stimuli-responsive MOFs in cancer therapy is highlighted, along with recent studies demonstrating the effectiveness of MOF-based drug delivery systems. Overall, MOFs offer opportunities for advancing cancer treatment and controlled drug delivery.

CA Cancer J Clin. 2025 Jan-Feb;75(1):10-45. (PMID: 39817679)
Angew Chem Int Ed Engl. 2006 Sep 11;45(36):5974-8. (PMID: 16897793)
Iran Biomed J. 2025 Jun 04;29(4):173-188. (PMID: 41048083)
Chem Soc Rev. 2022 Jan 24;51(2):464-484. (PMID: 34985082)
Curr Drug Targets. 2018;19(14):1696-1709. (PMID: 29577855)
Inorg Chem. 2021 Aug 16;60(16):11703-11705. (PMID: 34392689)
Biol Trace Elem Res. 2026 Feb;204(2):836-852. (PMID: 40553239)
Discov Oncol. 2025 Apr 24;16(1):607. (PMID: 40272602)
Biomaterials. 2020 Feb;230:119619. (PMID: 31757529)
Bioact Mater. 2025 Oct 30;56:559-570. (PMID: 41245074)
J Mater Chem B. 2023 Apr 12;11(15):3273-3294. (PMID: 36928915)
Front Chem. 2022 Mar 16;10:841316. (PMID: 35372266)
Chem Eng J. 2023 Sep 1;471:. (PMID: 39280062)
Inorg Chem. 2014 Feb 17;53(4):1916-24. (PMID: 24251853)
Cancer Rep (Hoboken). 2023 Aug;6(8):e1844. (PMID: 37279947)
Small. 2024 Nov;20(47):e2404350. (PMID: 39149999)
Front Pharmacol. 2023 Sep 06;14:1265440. (PMID: 37745070)
Sci Total Environ. 2024 Jan 1;906:167295. (PMID: 37742958)
Int J Pharm. 2025 Mar 30;673:125380. (PMID: 39988215)
Front Bioeng Biotechnol. 2022 Oct 21;10:1031986. (PMID: 36338113)
Adv Funct Mater. 2023 Nov 21;34(43):. (PMID: 39726715)
Heliyon. 2021 Apr 27;7(4):e06914. (PMID: 33997421)
Nat Mater. 2010 Feb;9(2):172-8. (PMID: 20010827)
Acta Biomater. 2022 Jun;145:43-51. (PMID: 35398545)
ACS Biomater Sci Eng. 2023 Aug 14;9(8):4497-4526. (PMID: 37526605)
J Phys Chem Lett. 2014 Oct 16;5(20):3468-79. (PMID: 26278595)
Nanomaterials (Basel). 2025 Jun 14;15(12):. (PMID: 40559289)
ADMET DMPK. 2023 Nov 17;12(1):27-62. (PMID: 38560715)
Pharmaceutics. 2017 Oct 14;9(4):. (PMID: 29036899)
Curr Pharm Des. 2015;21(38):5589-604. (PMID: 26429711)
Colloids Surf B Biointerfaces. 2023 Dec;232:113612. (PMID: 37898043)
J Am Chem Soc. 2025 Mar 05;147(9):7423-7432. (PMID: 39992360)
Biomaterials. 2017 Apr;122:23-33. (PMID: 28107662)
Ecotoxicol Environ Saf. 2021 Apr 15;213:112028. (PMID: 33607335)
J Nanobiotechnology. 2025 Feb 28;23(1):157. (PMID: 40022098)
Acta Pharm Sin B. 2022 Nov;12(11):4098-4121. (PMID: 36386470)
SAGE Open Med. 2021 Aug 12;9:20503121211034366. (PMID: 34408877)
Clin Transl Med. 2017 Dec 11;6(1):44. (PMID: 29230567)
Acta Pharm Sin B. 2021 Aug;11(8):2362-2395. (PMID: 34522591)
Nanomaterials (Basel). 2022 Jan 16;12(2):. (PMID: 35055294)
Inorg Chem. 2018 Nov 5;57(21):13364-13379. (PMID: 30351060)
Med Oncol. 2024 Dec 9;42(1):26. (PMID: 39653960)
Front Bioeng Biotechnol. 2024 Jun 13;12:1397804. (PMID: 38938982)
Colloids Surf B Biointerfaces. 2023 May;225:113266. (PMID: 36947901)
Curr Med Chem. 2017;24(2):193-214. (PMID: 27686655)
Small Methods. 2025 Jul;9(7):e2401808. (PMID: 40351034)
Polymers (Basel). 2022 Feb 26;14(5):. (PMID: 35267759)
J Funct Biomater. 2023 Nov 13;14(11):. (PMID: 37998115)
Drug Des Devel Ther. 2021 Oct 28;15:4455-4468. (PMID: 34737552)
Molecules. 2019 Mar 28;24(7):. (PMID: 30925694)
RSC Adv. 2024 Sep 23;14(41):30201-30229. (PMID: 39315019)
Theranostics. 2016 Jun 07;6(9):1306-23. (PMID: 27375781)
J Mater Chem B. 2021 Aug 4;9(30):5925-5934. (PMID: 34259304)
J Med Chem. 2014 Jul 10;57(13):5679-85. (PMID: 24922463)
Angew Chem Int Ed Engl. 2017 Dec 4;56(49):15565-15569. (PMID: 28960750)
Chem Mater. 2023 Jan 24;35(2):359-363. (PMID: 37799624)
Int J Biol Macromol. 2024 Dec;282(Pt 1):136648. (PMID: 39437945)
Pharmaceutics. 2023 Nov 07;15(11):. (PMID: 38004573)
J Phys Chem A. 2014 Dec 18;118(50):11696-707. (PMID: 25491413)
Biochimie. 2010 Sep;92(9):1242-51. (PMID: 20211678)
Int J Nanomedicine. 2021 Feb 17;16:1313-1330. (PMID: 33628022)
Eco Environ Health. 2025 Oct 11;4(4):100191. (PMID: 41215775)
Int J Biol Macromol. 2024 Mar;260(Pt 2):129391. (PMID: 38242413)

Keywords: cytotoxicity; drug loading; metal–organic framework; synthesis method

0 (Metal-Organic Frameworks)
0 (Antineoplastic Agents)
0 (Drug Carriers)

Date Created: 20260213 Date Completed: 20260213 Latest Revision: 20260216

20260216

PMC12897799

10.3390/ijms27031548

41683966